| HOME >> MEDICINE >> TECHNOLOGY |
1,028,000
(108,000)
(50,000)870,000Research and development
599,000
(14,000)
(1,000)584,000Selling and marketing
3,734,000
(60,000)
(13,000)3,661,000Amortization
216,000$(216,000)
-5,577,000
(182,000)
(64,000)
(216,000)
5,115,000Operating Loss
$(642,000)
$190,000
$73,000
$216,000
$(163,000)September 30, 2011Gross Profit
$4,208,000
$6,000
$8,000$4,222,000% of net sales
84.7%85.0%Operating ExpensesGeneral and administrative
942,000
(90,000)
(40,000)812,000Research and development
457,000
(11,000)
(3,000)443,000Selling and marketing
3,870,000
(53,000)
(13,000)3,804,000Amortization
214,000$(214,000)
-5,483,000
(154,000)
(56,000)
(214,000)
5,059,000Operating Loss
$(1,275,000)
$160,000
$64,000
$214,000
$(837,000)Expense AdjustmentsSix Months EndedGAAPShare-based ExpenseDepreciationAmortization of IntangiblesNon-GAAPSeptember 30, 2012Gross Profit
$9,756,000
$15,000
$18,000$9,789,000% of net sales
86.4%86.7%Operating ExpensesGeneral and administrative
2,120,000
(194,000)
(96,000)1,830,000Research and development
1,162,000
(26,000)
(2,000)1,134,000Selling and marketing
7,699,000
(120,000)
(30,000)7,549,000Amortization
431,000$(431,000)
-11,412,000
(340,000)
(128,000)
(431,000)
10,513,000Operating Loss
$(1,656,000)
$355,000
$146,000
$431,000
$(724,000)September 30, 2011Gross Profit
$8,152,000
$11,000
$15
'/>"/>
| SOURCE Uroplasty, Inc. Copyright©2012 PR Newswire. All rights reserved |